Title of cohort


The Vallecas Project

Acronym for cohort


Name of Principal Investigator - Title


Dr

Name of Principal Investigator - First name


Miguel

Name of Principal Investigator - Last name


Medina Padilla

Address of institution -Institution


CIEN Foundation

Address of institution - Street address


C/ Valderrebollo, 5

Address of institution - City


Madrid

Address of institution - Postcode


28031

Country


Spain

Website


http://www.fundacioncien.es/

Contact email


[email protected]

Funding source


[email protected]

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?


Alzheimer's disease and other dementias

Q1b. When are studies on the above condition(s) expected to become possible?


Already possible

Q2a. In a single sentence what is the stated aim of the cohort?


Identify various markers to eventually determine the potential risk that each individual could have to develop the disease in the future and determine an early detection of Alzheimer's Disease

Q2b. What distinguishes this cohort from other population cohorts?


Q3a. i) Number of publications that involve use of your cohort to date


Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)


Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available


Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population


Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:


70

Q4a. Study criteria: what is the age range of participants at recruitment? To:


85

Q4b. Study criteria: what are the inclusion criteria?


Signing an informed consent; be aged between 70 and 85 years old; availability and ability to reach the Alzheimer Centre for visits; and visual and hearing abilities that allow conducting the study tests.

Q4c. Study criteria: what are the exclusion criteria?


Suspected or diagnosed dementia; inability to perform neuroimaging studies; alcohol abuse; mental retardation; or history of certain psychiatric or neurological diseases

Q5. What is the size of the cohort (i.e. how many participants have enrolled)?


1,000-5,000 participants

Q6a. Please describe what measures are used to characterise participants


Sociodemographic, Clinical, Neuroimaging, Neurological and Neuropsychological measures

Q6b. Are there additional measures for participants with a clinical disorder?


Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?


No

If yes please specify


Q7. What is the study design (select all that apply)?


Prospective cohort|Longitudinal

Q8. Are your cases matched by


Age

Q9a. Does your study include a specialised subset of control participants?


Yes

Q9b. If your study includes a specialised subset of control participants please describe


Q10a. i) Please enter the data collection start date


01/01/2011

Q10a. ii) Please enter the data collection end date


Q10a. iii) Is data collection for this study


Data collection ongoing| Data analysis ongoing

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?


Q11. Is data collected


Other please specify here


Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?


Yes (participants given permission to be re-contacted via PIs)

Q13a. Please give information on the format and availability of data stored in a database (1)


% available


Q13a. Please give information on the format and availability of data stored in a database (2)


Database is web-based

% available


Q13a. Please give information on the format and availability of data stored in a database (3)


Database on spreadsheet (e.g. excel)

% available


Q13a. Please give information on the format and availability of data stored in a database (4)


% available


Other (please specify)


% available


Q13b. Please give information on the format and availability of data held as individual records (1)


% available


Q13b. Please give information on the format and availability of data held as individual records (2)


% available


Q13b. Please give information on the format and availability of data held as individual records (3)


Data held on computer based records

% available


Q13b. Please give information on the format and availability of data held as individual records (4)


% available


Please specify language used


Q14a. Is data available to other groups?


No

Q14b. If data is available to other groups what is the access policy/mechanisms for access?


Q15. What data sharing policy is specified as a condition of use?


No policy exists

Q16a. Are tissues/samples/DNA available to other groups?


Yes

Q16b i) If yes, please describe below:


Living donors: blood| Living donors: blood derivatives| Living donors: DNA| Post-mortem donors: brain

Q16b. ii) In what form are tissues/samples/DNA supplied?


Primary samples: Supplied fresh| Primary Samples: Stabilised samples (frozen or fixed)| Secondary samples:(derivatives of primary samples)| Secondary samples: plasma| Secondary samples: DNA| Secondary samples: RNA| Secondary samples: protein extracts| Secondary samples: cell lines derived from primary samples

Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?


No

Q17. Is information on biological characteristics available to other groups?


No

Number of Patients


% of total cohort

Export as PDF